Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • pharma-news
    • JnJ Faulty Hip...

    JnJ Faulty Hip Implants: 171 patients received compensation, says Ashwini Kumar Choubey

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2020-02-05T15:15:01+05:30  |  Updated On 5 Feb 2020 3:15 PM IST
    JnJ Faulty Hip Implants: 171 patients received compensation, says Ashwini Kumar Choubey

    "Based on the court order, a list of verified claimants along with supporting documents has been provided to Johnson and Johnson for complying with the court''s order. As per records, 171 patients have received compensation," Ashwini Kumar Choubey said.

    New Delhi: Around 171 patients have received compensation so far for faulty hip replacements from Johnson and Johnson, the Ministry of Health Affairs informed Parliament on Tuesday.

    Replying to a query in Rajya Sabha, Minister of State for Health Affairs Ashwini Kumar Choubey said the High Court of Delhi, on May 30 last year, ordered that the petitioner pay the sum of Rs 25 lakh to each verified claimant, without prejudice to the rights of the claimants.

    "Based on the court order, a list of verified claimants along with supporting documents has been provided to Johnson and Johnson for complying with the court''s order. As per records, 171 patients have received compensation," Choubey said.

    Also Read: JnJ Hip Implants: CDSCO Orders Compensation Of Over Rs 2 Crore For 2 More Patients

    The government had constituted a committee to examine the issues relating to faulty ASR Hip Implants. The committee, after a detailed examination of the issue, submitted its report to the government, which accepted the recommendations with some modifications.

    Based on the accepted recommendations, the government constituted a Central Expert Committee under the Chairmanship of Dr R K Arya, Director, Sports Injury Centre, Safdarjung Hospital, New Delhi, inter-alia to determine the quantum of compensation.

    "A formula for determining compensation for the affected patients has been formulated and placed in the public domain. The affected patients can approach either the Central Expert Committee or state-level committees constituted by the state governments as per their convenience.

    "M/s Johnson & Johnson Pvt. Ltd. was asked to comply with the recommendations of the committee and to pay the compensation as per the formula approved by the government in the interest of the patients. However, M/s Johnson & Johnson Pvt. Ltd. challenged the expert committee report on payment of compensation before the Honourable High Court of Delhi," he said.

    Also Read: JnJ Faulty Hip Implants: 7 More Patients Found Fit For Compensation

    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok